Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022

Description:
Oncological segment has gained a great momentum with the advent of modern technologies and the better equipped sequencing methodology. Over the past years, there has been gradual paradigm shift from traditional medicine and accelerated acceptance towards the precision medication. Physicians are opting for the personalization of the medicines according to the genomic makeup of the patient.

During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemotherapy and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. The upsurge of immunotherapeutics in oncology is remarkable and the trail towards getting personalized is in future trends. With the development of the pharmacogenomics and genome mapping resolutions towards human genome are making personalized vaccines to be more efficacious. The platform for the personalization of vaccines had been built by the human genome project.

Geographically, the acceptance of personalization is greater in the western world as both the new and old vaccine approaches towards the cancer are transforming the landscape of the major markets of western world including US, Western Europe and Japan. In contrary the concept is less influential in the low and middle income countries. Nevertheless, in the upcoming time the improvement will surely administer the challenges of cost and distribution which will aid the personalization in the Asia-Pacific regions.

The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

In contrary, it also provides better future opportunities for pharmaceuticals too although there are several challenges and unmet needs which has to be defined first. Many pharmaceutical companies have calculated the improvised vision for the right drug, right patient and the right time. This concept saves the resources, time and provides ample opportunities to achieve substantial medications for the investors.

The future potential of personalized cancer vaccines for the detection, management and preventing diseases is primarily dependent on the ongoing genomic projects, merging translational medicines and advances in personal genetic testing and developing targeted therapy. Such innovative therapies are also welcomed by the physicians as these approaches minimize the trial and error diagnosis and treatment. The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

The report “Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022” is an inclusive report which covers the current and future opportunities for the personalized cancer vaccines and its varied inclinations in oncology. The report throws a light over the clinical relevance of personalized forms and identifies the risk and commercial aspects along with the potential outcome for the success of personalized cancer vaccines in the upcoming future directions.

“Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022” Report Highlights:

- Introduction to Personalized Cancer Vaccines
- Identification of Tumor Neoantigens
- Development & Mechanism of Personalized Vaccines
- Categories of Personalized Cancer Vaccines
- Biomarkers for Personalized Vaccines
- Personalized Vaccines for Multiple Cancers
- Current & Future Market Outlook of Personalized Cancer Vaccines
12.1.4 Government Initiatives
12.1.5 Reduced Genome Sequencing Cost & Time
12.1.6 Sustained Level of Innovation
12.2 Personalization Major Challenges

13. Global Personalized Cancer Vaccines Market Future Aspects

14. Competitive Landscape
14.1 Advaxis Inc.
14.2 Avax Technologies
14.3 BioNtech
14.4 Celldex
14.5 Genentech Inc.
14.6 Genocea
14.7 ISA Pharmaceuticals
14.8 Merck & Co.
14.9 Moderna
14.10 Neon Therapeutics

List of Figures:
Figure 1-1: Categorization of the Cancer Immunotherapeutics Towards Cancer Vaccines
Figure 1-2: Illustration of Advantages Provided by the Targeting Neoantigens
Figure 2-1: Distinguishing Features of Driver & Passenger Gene Mutations
Figure 3-1: Identification of Tumor Antigens by Conventional Approach
Figure 3-2: Number of Mutation Derived Neoantigens in Human Cancer
Figure 3-3: Identification of Tumor Specific Neoantigens by Next Generation Sequencing
Figure 4-1: Illustration of Development of personalized Cancer Vaccines
Figure 4-2: Estimated Cost for Cancer Cell's Genome Sequencing (US$)
Figure 4-3: Estimated Economic (US$) & Timeline (Weeks) Projections of Personalized Cancer Vaccine
Figure 5-1: Illustration of Development of Personalized Cancer Vaccines
Figure 5-2: Immune Stimulation by T-Cells with Personalized Cancer Vaccine
Figure 5-3: Immune Response Stimulation by B Cells with Personalized Cancer Vaccines
Figure 6-1: Route of Action of Adoptive T-Cell Mechanism in Individual
Figure 6-2: Clinical Aspects of Tumor Infiltrating T Cells in Cancer
Figure 6-3: Typical Mechanism of T Cell Activation via Signal Binding
Figure 6-4: Schematic Representation of Evolution of CARs Design
Figure 6-5: Mechanism of Cell Checkpoint Blockade in Cancer Vaccines
Figure 6-6: Mechanism of Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4)
Figure 6-7: Mechanism of PD-L1 Checkpoint Blockade in Tumor Cells
Figure 7-1: Differences between Conventional & Personalized Peptide Vaccine
Figure 7-2: The Representation of Template of a Polypeptide DNA Vaccine
Figure 7-3: Principle Structure of Synthetic m-RNA Developed with Specific Antigen
Figure 7-4: Representation of Ex-Vivo Preparation of Dendritic Cell based Vaccines
Figure 7-5: The Tumor Microenvironment Suppresses Efficacy by DC based Vaccines
Figure 7-6: Mechanism of Personalized Autologous Whole Tumor Cancer Vaccine
Figure 7-7: Representation of Replicative Virus Encoding a HSP Gene for Antitumor Activity
Figure 8-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 8-2: Roadmap of Development of Predictive Biomarkers
Figure 8-3: High Throughput Immune Assessment for Biomarker Discovery
Figure 9-1: Alterations in Mechanism of Cell Cycle Control of CDKN2A
Figure 9-2: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Figure 9-3: Personalized Strategies to Attain the Target of Interest in Acute Myeloid Leukemia
Figure 9-4: Prevalence of Cervical Cancer in Women in Developed & Developing Countries
Figure 9-5: Proportion of Genetic Abnormalities Present in Gastric Cancer
Figure 9-6: Classification of Gliomas into Four Grades Based as WHO Classification
Figure 9-7: Illustration of Loss of VHL Expression Leads to Renal Cell Carcinoma
Figure 10-1: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 10-2: The Sources of Pharmacological & Pharmacogenetic Variability's
Figure 10-3: Applications of Pharmacogenomics in Cancer Precision Medicines
Figure 11-1: Personalized Cancer Vaccine Market Opportunity Assessment (US$ Million), 2017-2022
Figure 11-2: Representation of the Commercial Oncological Trials by Segment
Figure 12-1: Representation of Growth Drivers in Personalized Cancer Vaccines
Figure 12-2: Illustrations of the Reduced Sequencing Cost of Human Genome
Figure 12-3: Major Challenges faced by the Personalized Cancer Vaccines

Ordering:

Order Online - http://www.researchandmarkets.com/reports/4077034/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022
- **Web Address:** [http://www.researchandmarkets.com/reports/4077034/](http://www.researchandmarkets.com/reports/4077034/)
- **Office Code:** SC2GBN9D

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
</tr>
<tr>
<td>CD-ROM</td>
<td>USD 3000 + USD 56 SH/</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>USD 3600 + USD 56 SH/</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

- **Title:** [Mr, Mrs, Dr, Miss, Ms, Prof]
- **First Name:**
- **Last Name:**
- **Email Address:** *
- **Job Title:**
- **Organisation:**
- **Address:**
- **City:**
- **Postal / Zip Code:**
- **Country:**
- **Phone Number:**
- **Fax Number:**

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World